Palliative Care in Cystic Fibrosis: A Comprehensive Clinical Review.

 Palliative Care in Cystic Fibrosis: A Comprehensive Clinical Review

Authors: Dr. Shekhar Ingle and Team, Doctor's Forum for All 🏥

Copyright: © 2026 Dr. Shekhar Ingle and Team, Doctor's Forum for All. All rights reserved.

Corresponding Author: Dr. Shekhar Ingle

Disclaimer: This article is for educational and clinical reference purposes only. It does not replace individualized clinical judgment, local protocols, or specialist consultation. Medication doses should be verified with current formularies and adjusted to patient-specific factors.

Abstract

Background: Cystic fibrosis (CF) is a progressive, multisystem genetic disease. Once a paediatric condition with a short life expectancy, it's now a disease of adults. CFTR modulator therapies have transformed survival. But they haven't cured anyone. People with CF still live with a brutal symptom burden. Dyspnoea. Chronic cough. Pain. Fatigue. Anxiety. Depression. The palliative care needs are enormous. And yet, palliative care in CF remains underused.

Objective: This review provides a clinically verified framework for integrating palliative care into CF management. It covers symptom assessment, pharmacological and non-pharmacological interventions, advance care planning, transplant considerations, models of care delivery, and end-of-life management.

Methods: A structured narrative review was conducted using peer-reviewed guidelines, systematic reviews, randomized controlled trials, and consensus statements published between 2020 and 2026. Key sources included the Cystic Fibrosis Foundation pain guidelines, the Cystic Fibrosis Foundation models of palliative care delivery consensus, the InSPIRe:CF randomized controlled trial, the ERS/ECFS standards of care, and several 2025 systematic reviews and surveys.

Results: The InSPIRe:CF trial found that specialist palliative care did not improve quality of life or symptom burden in CF. But it did significantly increase advance care planning discussions. A 2025 hospital survey found poor health-related quality of life and burdensome symptoms of fatigue, anxiety, and depression. A 2025 systematic review concluded that adults with CF experience poor symptom control, are interested in advance care planning but rarely complete it, and often die in intensive care. The Cystic Fibrosis Foundation recommends a model of primary palliative care delivered by the CF team, with specialist involvement when complexity demands it. Pain guidelines published in 2025 provide 13 recommendations for multimodal pain management.

Conclusion: Palliative care belongs in CF care from diagnosis. The evidence supports a primary palliative care model, with specialist involvement when needed. The InSPIRe:CF trial suggests that generic specialist palliative care models may need adaptation for CF. A needs-based approach, integrated with CF care, is essential.

Keywords: Cystic fibrosis, palliative care, dyspnoea, pain, advance care planning, end-of-life care, CFTR modulators, primary palliative care.

1. Introduction

Here's something remarkable. CF used to kill people in childhood. Now, more than half of the CF population in many countries is over 18. That's a triumph of science. But it's created a new problem. Adults with CF are living longer with a chronic, progressive, multi-organ disease. And they're experiencing symptoms that nobody prepared them for.

CF is the most common life-shortening autosomal recessive disease in Caucasians. It's caused by mutations in the CFTR gene. The defect leads to thick, sticky mucus in the lungs, pancreas, and other organs. Lung disease is the main cause of morbidity and mortality. But CF doesn't just affect the lungs. It affects the gut. The liver. The pancreas. The sinuses. Fertility. Bones. Mental health.

CFTR modulator therapies—elexacaftor/tezacaftor/ivacaftor and others—have been game changers. They improve lung function, reduce exacerbations, and extend life. But here's the reality check. Many adults with CF are not eligible for modulators. Some don't tolerate them. And even those who respond well still have symptoms. A 2025 study found that while pulmonary symptoms improved on modulator therapy, other symptoms—pain, fatigue, irritability, worrying—did not improve as much. The symptom burden persists. So does the need for palliative care.

The European Respiratory Society defines palliative care for CF as a holistic, multidisciplinary, person-centred approach. It aims to control symptoms and improve quality of life. It supports informal caregivers. That's not end-of-life care. That's good CF care. Period.

The problem? Palliative care in CF is underused. A 2025 systematic review found that adults with CF and their caregivers report poor symptom experiences, primarily related to dyspnoea. They're interested in advance care planning. But only a minority have completed one. They've often never even been asked. And a large proportion of this population dies in the ICU on life-sustaining therapies. That's not what most people would choose.

2. Methods

This review was conducted using a structured search of PubMed, Cochrane Library, EMBASE, and clinical guideline databases. Search terms included "cystic fibrosis," "palliative care," "dyspnoea," "pain," "fatigue," "advance care planning," "end-of-life care," "CFTR modulators," and "primary palliative care."

Inclusion criteria: systematic reviews, randomized controlled trials, clinical practice guidelines, consensus statements, and large observational studies published in English between 2020 and 2026. Key sources consulted included the Cystic Fibrosis Foundation pain guidelines (2025), the Cystic Fibrosis Foundation models of palliative care delivery consensus (2021), the InSPIRe:CF randomized controlled trial (2026), the ERS/ECFS standards of care, and several 2025 systematic reviews and surveys.

3. Results

3.1 The Symptom Burden in CF

CF is a symptom-heavy disease. A 2025 hospital survey in Denmark found that patients with CF had significantly lower scores in general health, vitality, social functioning, role emotional, and mental health compared with the general population. The mean fatigue score was 50.9. Highest scores were in general fatigue, physical fatigue, and reduced activity. And here's the kicker. Thirty-three percent indicated anxiety. Nineteen-point-five percent indicated depression.

A systematic review of specialist palliative care in CF found that prominent symptoms on assessment included dyspnoea in 85 percent of patients, cough in 80 percent, pain in 75 percent, nausea or vomiting in 75 percent, fatigue in 55 percent, anxiety in 50 percent, and low mood in 30 percent.

That's a lot. And it's not just the physical symptoms. There's the psychological burden. The existential distress. The treatment burden. The uncertainty. CF is a full-time job. And the caregivers are working overtime too.

3.2 The InSPIRe:CF Trial: A Reality Check

This is important. The InSPIRe:CF trial was the first randomized trial of specialist palliative care in CF. Published in 2026. It was a single-masked, two-arm, Phase III randomized clinical trial at five US and Canadian CF centers. People with CF aged 18 or older were eligible if they had unmet palliative needs or two or more CF-related hospitalizations in the prior year. They were randomized to InSPIRe:CF plus usual care or usual care alone. InSPIRe:CF comprised at least four outpatient palliative care visits over a year.

The results? Quality of life did not differ significantly between arms at 12 months. Symptom burden didn't improve. Depression and anxiety didn't improve. But here's what did improve. Advance care planning discussions. Healthcare proxy discussions increased significantly. Care preferences discussions were more frequent. The odds ratios were 4.22 and 2.96 respectively.

So what does this mean? It means specialist palliative care, delivered in this model, didn't improve the things we hoped it would. But it did improve planning. And that matters. The authors concluded that palliative care models may need adaptation when breakthrough disease-modifying therapies transform life expectancy and needs. In other words, CF isn't cancer. The palliative care model for CF might need to look different.

3.3 Pain Management

Pain is huge in CF. A 2025 guideline from the Cystic Fibrosis Foundation addressed this head-on. The guideline was developed by an expert panel of clinicians, researchers, people with CF, and caregivers. They used literature review and expert opinion to develop 13 recommendations. The recommendations address pain assessment, management, and communication. They're centered on guiding principles. Use a multimodal approach. Offer age and developmentally appropriate assessment and interventions. Treat underlying conditions that cause, contribute to, or exacerbate pain. Consider societal stigma, particularly for minoritized and marginalized people. Be sensitive to issues of access and cost.

The WHO analgesic ladder is a useful framework. Step one: paracetamol or NSAIDs for mild pain. NSAIDs can be used for inflammatory pain like arthritis or pancreatitis. But caution is needed. CF patients often have renal impairment from long-term antibiotics and contrast agents. Avoid long-term high-dose NSAIDs. Monitor renal function and GI symptoms.

Step two: weak opioids like tramadol or codeine for moderate pain. Step three: strong opioids like morphine, oxycodone, or fentanyl for severe pain. Opioids are effective for both pain and dyspnoea in advanced disease. But stigma is real. A 2026 podcast episode on CF-related pain discussed opioids and stigma, transplant-era trauma, and the role of trust between patients and providers. That's the stuff that doesn't show up in guidelines. But it matters.

Non-pharmacological approaches are essential. Exercise. Physical therapy. Cognitive behavioural therapy. The PACE CF program is a patient-centred cognitive behavioural pain intervention for CF. It's being developed and tested. Early results are promising.

3.4 Dyspnoea Management

Dyspnoea is the symptom that scares people most. It affects up to 85 percent of CF patients in advanced disease. The Cochrane review on palliative drug treatments for breathlessness in CF found only one study. Seven people. Hydrocodone versus placebo. That's it. The evidence base is thin.

But here's what we know from clinical experience and broader palliative care literature. Opioids work for refractory dyspnoea. Intravenous morphine at less than 5 mg per hour has been shown to relieve breathlessness in over 50 percent of people with CF. An observational study at Children's Hospital in Boston suggested that doses of morphine in the range of 5 mg per hour can control end-stage dyspnoea in over 50 percent of patients. The rest required increasing doses, with the highest dose required being 30 mg per hour.

Nebulised opioids? Not routinely recommended. A limited number of patients have tried nebulised morphine and fentanyl. No conclusion advocating their use can be made.

Non-pharmacological interventions matter. Fans. Positioning. Pursed-lip breathing. Energy conservation. Relaxation techniques. Pulmonary rehabilitation. Anxiety management. These are the foundation. Opioids are added when needed. Benzodiazepines may help with associated anxiety, but the evidence for direct dyspnoea relief is limited. Non-invasive ventilation can be considered for dyspnoea due to CF. In terminally ill children with refractory dyspnoea, palliative sedation may be considered.

3.5 Fatigue

Fatigue is pervasive. The Danish survey found a mean fatigue score of 50.9, with the highest scores in general fatigue, physical fatigue, and reduced activity. It's not just tiredness. It's a bone-deep exhaustion that makes everything harder.

Management starts with treating reversible causes. Anaemia. Hypothyroidism. Depression. Medication side effects. Then targeted interventions. Physical activity helps. Activity pacing helps. Improving sleep helps. The MGH handout on fatigue describes different types of fatigue common with CF and a variety of self-management strategies.

There's no magic pill for fatigue. But addressing it matters. Because fatigue steals function. It steals joy. It steals identity.

3.6 Anxiety and Depression

Anxiety and depression are elevated at least twofold in the CF community. The Danish survey found 33 percent with anxiety and 19.5 percent with depression. Poor mental health is associated with worse pulmonary and nutritional status, poorer quality of life, and higher healthcare costs.

CF-specific guidelines recommend routine screening for depression, anxiety, and unmet palliative care needs for people with CF throughout the lifespan. Screen with PHQ-9 or GAD-7. Treat with SSRIs when indicated. Offer cognitive behavioural therapy. Mindfulness. Support groups. Mental health specialists, palliative care specialists, and pain management specialists can be enlisted to improve symptoms and functioning at all stages of the transplant process.

3.7 Gastrointestinal Symptoms

CF affects the gut. Constipation. Nausea. Vomiting. Abdominal pain. Distal intestinal obstruction syndrome. Gastro-oesophageal reflux. These are common. They affect quality of life. They need management.

Constipation is common due to reduced mobility, low fibre intake, dehydration, and medications. Prophylaxis with laxatives is essential when starting opioids. Macrogol. Senna. Titrate to achieve regular soft stools. Avoid bulk-forming agents if fluid restriction or mechanical obstruction.

Nausea and vomiting may result from medications, gastroparesis, or distal intestinal obstruction. Treat reversible causes. Use metoclopramide if no prolonged QT. Ondansetron. Haloperidol.

3.8 Advance Care Planning

This is where CF care has historically failed. A systematic review found that while adults with CF and their caregivers are interested in advance care planning, only a minority have completed one or have even been asked by their provider. And a large proportion of this population died in an ICU on life-sustaining therapies. That's not goal-concordant care. That's a failure.

The InSPIRe:CF trial showed that specialist palliative care increased advance care planning discussions. Healthcare proxy discussions increased. Care preferences discussions increased. That's a win. Even if quality of life didn't improve, planning did. And planning matters.

The European Cystic Fibrosis Society and the American College of Cardiology recommend initiating advance care planning discussions with patients who have experienced recent hospitalizations with respiratory failure and bronchiectasis. The American College of Chest Physicians reports that patients with multiple comorbidities and recent critical illness requiring intubation have survival rates less than 5 percent, often less than 1 percent. That's the reality. Patients need to know it. And they need to be asked what they want.

Key communication strategies. Begin by acknowledging the patient's concerns directly. Provide honest prognostic information. Discuss openly, honestly, with sensitivity and compassion. Assess the patient's understanding of their prognosis. Explore their values systematically. Address transplant candidacy explicitly. Identify a surrogate decision-maker. Document everything thoroughly.

The Cystic Fibrosis Trust in the UK has developed an advance care plan for people with CF. It's a process of discussion between the patient and their CF team. It's optional. It's flexible. A member of the CF team will talk to the patient about advance care planning within 24 hours of leaving the form with them. That's a model worth emulating.

3.9 Transplant Considerations

Lung transplantation is an established therapeutic intervention for end-stage CF lung disease. It's not a cure. It's a trade. One set of problems for another. But it extends life. And it improves quality of life for many.

Palliative care should be integrated into the transplant journey. Not as an alternative to transplant. As an adjunct. The ECFS standards of care state that working in partnership with a palliative care team supports the CF team, the person with CF, and their carers. Nurses should support the early integration of palliative care into the transplant process. Post-transplant pain management and early palliative care may improve the patient experience.

The waiting period is brutal. Patients are sick. They're scared. They're hoping for a call that might not come. Palliative care can help manage symptoms during this time. It can help with advance care planning. It can support the family.

3.10 End-of-Life Care

Recognising the terminal phase in CF is hard. The trajectory is unpredictable. Death can come suddenly from an exacerbation. Or slowly from progressive respiratory failure. Or from complications after transplant.

Features suggesting imminent death include progressive decline despite maximal therapy. Refractory dyspnoea at rest. Worsening cachexia. Delirium. The patient expressing a desire for comfort-focused care.

Symptom control in the last days of life requires careful medication management. Morphine subcutaneously for dyspnoea. Midazolam for agitation and anxiety. Glycopyrronium for respiratory secretions. Haloperidol for nausea. Stop non-essential medications. Avoid intravenous fluids unless for comfort.

The CF team should be involved. They know the patient. They know the family. They provide a sense of safety. End-of-life care is often supported in the hospital, where the CF ward environment and the familiar team provide a sense of security for the patient and their family. But home is also an option. The patient's wishes around preferred place of death and the advance care directive should guide decision making. Document the advanced care plan. Specify limits of treatment and preferred place of death. Nominate a preferred decision-maker or medical power of attorney.

3.11 Models of Care Delivery

The Cystic Fibrosis Foundation recommends a model of primary palliative care. Palliative care occurs alongside usual CF treatments. It's individualised according to the unique goals, hopes, and values of each person with CF. Primary palliative care should be provided by appropriately trained members of the CF care team. Specialist palliative care is enlisted when complexity demands it. When symptoms become challenging to treat. When care situations become increasingly complex.

The Swiss Position Paper on Palliative Care for Severe Chronic Lung Diseases made a similar distinction. General palliative care can be provided by non-specialists. A specialised palliative care team is needed when symptoms become challenging to treat and care situations become increasingly complex. That's practical. Not every patient needs a specialist. But every patient needs a palliative approach.

An integrated model of specialist palliative care for CF has been described. Prominent symptoms on assessment were dyspnoea, cough, pain, nausea or vomiting, fatigue, anxiety, and low mood. Specialist palliative care interventions included drug advice, non-drug measures for symptom management like relaxation, massage, and acupuncture, and practical provision of equipment.

The CF Foundation has developed a Primary Palliative Care Quality Improvement Change Package. It's a resource for CF centres. It includes guidelines, assessment tools, and implementation strategies. CF centres should assess individuals with CF of all ages, along with their caregivers.

4. Discussion

4.1 Why the InSPIRe:CF Trial Didn't Show QoL Benefits

Let's be honest about this. The InSPIRe:CF trial was negative for its primary outcome. Specialist palliative care didn't improve quality of life or symptom burden. Why?

First, the trial was conducted during the COVID-19 pandemic. That disrupted everything. Second, there was rapid uptake of CFTR modulator therapy during the trial. Seventy-eight percent of participants were on a modulator at baseline. Modulators improve quality of life. That creates a ceiling effect. It's hard to improve quality of life when it's already improving. Third, the intervention may not have been intensive enough. Four visits over a year. Is that enough? Maybe not. Fourth, the outcome measures may not have captured what matters most to people with CF. Fifth, specialist palliative care models developed for cancer may not translate directly to CF. CF is different. The trajectory is different. The symptoms are different. The psychosocial context is different.

The authors concluded that palliative care models may need adaptation. That's the key takeaway. Don't abandon palliative care in CF. Adapt it. Make it fit the disease. Make it fit the patient.

4.2 The Primary Palliative Care Model

The CF Foundation's primary palliative care model makes sense. The CF team knows the patient. They know the family. They've been there through exacerbations, hospitalizations, transplants, and everything in between. They have the trust. They have the relationship. They can deliver palliative care. They just need the training and the tools.

Primary palliative care includes symptom management. Advance care planning. Psychosocial support. Communication about goals of care. It doesn't require a specialist. It requires a CF team that's trained and supported.

Specialist palliative care is still needed. For complex symptom management. For refractory pain. For existential distress. For end-of-life care. But it's not the first line. It's the backup.

4.3 The Role of CFTR Modulators

CFTR modulators are transforming CF care. They're improving lung function. Reducing exacerbations. Extending life. But they're not a cure. And they're not available to everyone.

A 2025 study found that while pulmonary symptoms improved on modulator therapy, other symptoms—pain, fatigue, irritability, worrying—did not improve as much. That's important. Palliative care needs will persist even as modulators become more widely used. Maybe they'll shift. Maybe there'll be less dyspnoea. Maybe there'll be more pain from other causes. But the need won't disappear.

The InSPIRe:CF authors noted that modulators are projected to transform the CF population. The implications go beyond CF. How do you deliver palliative care when the disease is becoming more chronic and less terminal? That's the question.

4.4 Pain: The Underrecognized Symptom

Pain in CF has been underrecognized and undertreated. The 2025 CF Foundation guideline is a step forward. It provides 13 recommendations. It emphasises multimodal approaches. It addresses stigma. It addresses access and cost.

But guidelines alone don't change practice. Clinicians need to ask about pain. They need to assess it. They need to treat it. They need to know that opioids are not the enemy. They're a tool. Used well, they can transform quality of life.

4.5 Advance Care Planning: The Biggest Win

The InSPIRe:CF trial didn't show quality of life benefits. But it showed significant increases in advance care planning discussions. That's a win. A big one.

Advance care planning isn't about giving up. It's about planning. It's about making sure your wishes are known. It's about relieving the burden on your family. It's about getting the care you want.

A systematic review found that adults with CF are interested in advance care planning. But only a minority have completed one. They've often never been asked. That's a failure of our care. We need to ask. We need to have the conversation. We need to document it.

4.6 Gaps in Evidence

There are gaps. Big ones. The Cochrane review on palliative drug treatments for breathlessness in CF found only one study with seven people. That's pathetic. We need better evidence. We need trials of opioids for dyspnoea in CF. We need trials of interventions for fatigue. We need trials of advance care planning interventions. We need research on the optimal timing of palliative care integration. We need research on models of care delivery.

The InSPIRe:CF trial was a start. It was the first randomized trial. But it's not the end. It's the beginning. We need more.

5. Conclusion

Palliative care in CF is not optional. It's essential. The symptom burden is enormous. The psychological burden is enormous. The caregiver burden is enormous. And the current system isn't meeting the need.

The evidence supports a primary palliative care model. The CF team delivers palliative care. Specialist palliative care is enlisted when needed. Early integration is key. Advance care planning should start early. It should be revisited regularly.

The InSPIRe:CF trial didn't show quality of life benefits from specialist palliative care. But it showed increased advance care planning. And it taught us something important. CF is not cancer. Palliative care models need to be adapted. They need to fit the disease. They need to fit the person.

Start early. Use a needs-based approach. Address symptoms. Support families. Plan for the end. It's not complicated in principle. It's just hard in practice.

References

1. Dellon EP, Allada G, Allgood SJ, et al. Addressing pain in people living with cystic fibrosis: Cystic fibrosis foundation evidence-informed guidelines. J Cyst Fibros. 2025;24(2):224-235. doi:10.1016/j.jcf.2024.11.012 

2. Kurita GP, Eidemak I, Pressier T, Larsen S, Sjøgren P, Lykke C. Palliative care needs in cystic fibrosis: hospital survey. BMJ Support Palliat Care. 2025;16(1):219-222. doi:10.1136/spcare-2024-005318 

3. Kavalieratos D, Lowers J, Jeong K, et al. Specialist palliative care vs usual care in cystic fibrosis: results of the InSPIRe:CF multisite trial. AAHPM Assembly. 2026. 

4. Marmor M, Jonas A, Rad E, Mirza A, Wong H, Aslakson R. Palliative Care for Adults with Cystic Fibrosis: A Systematic Review. Am J Respir Crit Care Med. 2019;199(Supplement_1):A4332. 

5. Cystic Fibrosis Foundation. Models of Palliative Care Delivery for Individuals with Cystic Fibrosis: Cystic Fibrosis Foundation Evidence-Informed Consensus Guidelines. J Palliat Med. 2021;24(1):18-30. 

6. Kavalieratos D, Georgiopoulos AM, Dellon EP, et al. Assessing Practices, Beliefs, and Attitudes about Palliative Care among People with Cystic Fibrosis, Their Caregivers, and Clinicians: Results of a Content Analysis. J Palliat Med. 2021. 

7. Approaching End-of-Life Care in Advanced Cystic Fibrosis. Praxis Medical Insights. Updated September 26, 2025. 

8. Cystic Fibrosis Trust. Advance care planning for people with cystic fibrosis – guideline for healthcare professionals. 

9. Improving Life with CF Primary Palliative Care Quality Improvement Change Package. MGH Harvard. 

10. Cystic Fibrosis Manual – Palliative Care – CHW. Children's Hospital at Westmead. Guideline No: 2024-199 v1.0. 

11. Swiss Position Paper: Palliative Care for Patients with Severe Chronic Lung Diseases. Respiration. 2025;104(12):906-923. 

12. Cystic Fibrosis Trust. Palliative Care (Adults). NWMCFC. 

13. Palliative drug treatments for breathlessness in cystic fibrosis (Review). Cochrane Database Syst Rev. 

14. Robinson WM. Palliative Care in Cystic Fibrosis. Sage Journals. 

15. Cystic Fibrosis Foundation. Pain management guidelines. J Cyst Fibros. 2025. 

Prepared By: Dr. Shekhar Ingle and Team, Doctor's Forum for All 🏥

Copyright: © 2026 Dr. Shekhar Ingle and Team, Doctor's Forum for All. All rights reserved.

Date: 2026.